For instance, STM2457, a recently unearthed inhibitor of METTL3, has demonstrated significant antineoplastic efficacy against leukemia in both laboratory and animal models, thereby affirming the potential of METTL3 as a viable target in anticancer therapeutics [13]. Here, METTL3 is linked to leukemia.